Amgen (AMGN) CEO Bob Bradway on Q2 2014 Results – Earnings Call Transcript

Source: Seeking Alpha

 

Amgen (NASDAQ:AMGN)

Q2 2014 Results Earnings Conference Call

July 29, 2014, 5:00 p.m. ET

Executives

Arvind Sood – VP of Investor Relations

Bob Bradway – Chairman and CEO

David Meline – CFO

Tony Hooper – Head of Global Commercial Operations

Sean Harper – Head of R&D

Analysts

Matthew Harrison – Morgan Stanley

Robyn Karnauskas – Deutsche Bank

Eric Schmidt – Cowen & Company

Terence Flynn – Goldman Sachs

Geoffrey Porges – Sanford C. Bernstein

Josh Schimmer – Piper Jaffray

Yaron Werber – Citi

Mark Schoenebaum – ISI Group

Michael Yee – RBC Capital Markets

Geoff Meacham – JPMorgan

Matt Roden – UBS

Eun Yang – Jefferies

Ian Somaiya – Nomura Securities

Ravi Mehrotra – Credit Suisse

Howard Liang – Leerink Swann

Operator

My name is Marvin, and I will be your conference facilitator today for Amgen’s second quarter earnings conference call. [Operator instructions.] I would now like to introduce Arvind Sood, vice president of investor relations. Mr. Sood, you may now begin.

Arvind Sood – VP of Investor Relations

Okay, thank you, Marvin. Good afternoon, everybody. I’d like to welcome you to our conference call to review our operating results for the second quarter. Our new CFO, and my new boss, David Meline, actually picked a great quarter to join us, as our business performance was strong across the board.

Our CEO, Bob Bradway will introduce David formally in just a couple of minutes, and will also review our strategic progress and actions we are taking to position ourselves for long term growth. Following Bob, David will review our second quarter performance.

Our head of global commercial operations, Tony Hooper, will then discuss our product performance during the quarter and trends that we see going forward. Following Tony, our head of R&D, Sean Harper will provide a brief update on the many late-stage opportunities we have in our pipeline, as well as progress we are making on regulatory submissions. After Sean’s comments, Bob will make a few concluding comments, and then we should have plenty of time for Q&A.

ALSO READ:   Pfizer's (PFE) CEO Ian Read on Q2 2014 Results - Earnings Call Transcript

We will use slides for our presentation today. These slides have been posted on our website and a link was sent to you separately by email. You will notice that we have made some significant additions to our quarterly slide deck. This change was made in the spirit of providing more disclosure to further your understanding of our product trend drivers. And of course this will give my friend Mark Schoenebaum something to talk about in his next few weekly videos.

Our comments today will be governed by our Safe Harbor statement, which in summary says that through the course of our presentation and discussion today, we may make certain forward-looking statements and actual results may vary materially.

So with that, I would like to turn the call over to Bob. Bob?

Bob Bradway – Chairman and CEO

Thank you, Arvind. Let me begin by welcoming David Meline as our chief financial officer. David joins us from 3M, and his financial leadership and broad international experience will be very helpful to Amgen as we execute our strategy for long term growth and launch our pipeline of medicines in a number of new geographies. I’d also like to thank Michael Kelly for serving as our acting CFO prior to David’s appointment.

Our performance was strong across the board in the second quarter, and our confidence in the business is buoyed by our 11% revenue growth, 30% operating income growth, and 25% earnings per share growth for the period. Our recently launched and legacy brands performed well in the U.S. and in internationally, and we exercised expense discipline across the business to drive these results.

Based on our progress through the first half of the year, and our confidence in the underlying trends of the business, we’re raising guidance, as David will explain shortly.

Because we’ll be talking on this call both about our quarterly results and some restructuring activity, I’d like to take just a moment to set some strategic context. Our strategy for long term growth begins with a commitment to developing a robust, differentiated pipeline of new medicines addressing serious illness.

ALSO READ:   Merck's (MRK) CEO Ken Frazier on Q2 2014 Results - Earnings Call Transcript

This strategy is beginning to bear fruit. We’ve talked about our substantial portfolio of 10 late-stage molecules delivering pivotal data by 2016. So far in 2014, we’ve reported positive pivotal data for five of these molecules and we have submitted two of them already in the U.S., ivabradine for chronic heart failure, and TVEC for malignant melanoma.

In Q3, we expect to submit evolocumab in the U.S. and Europe, TVEC in Europe, and later in the year, blinatumomab in the U.S. with a breakthrough therapy designation. This presents us with the prospect of several high-potential new product launches beginning in 2015.

To capitalize on this opportunity, we announced today the first steps of a restructuring plan designed to improve our focus and proactively reallocate resources ahead of the commercialization of our many promising molecules, on a cost-competitive basis.

Our initial efforts include streamlining our organization, reducing layers of management, increasing managerial spans of responsibility, and beginning implementation of a revised geographic site plan. In this regard, we’ll reduce our workforce by between 2,400 and 2,900 positions, beginning in the fourth quarter of 2014 and continuing through 2015, predominantly in the United States. This represents approximately 12% to 15% of Amgen’s global workforce of some 20,000 staff members.

A significant element of our current restructuring plan involves optimizing our sites in the United States. As part of this, we plan to close all of our facilities in Washington and Colorado before the end of 2015. We’ll begin the process of exiting these sits in the third quarter of this year. These sites were primarily research and development and manufacturing facilities.

Pages: First |1 | 2 | 3 | ... | Next → | Last | Single Page View

Leave a Comment

Scroll to Top